Fig. 1From: Effects of GLP-1 receptor agonists and SGLT-2 inhibitors on cardiac structure and function: a narrative review of clinical evidenceUnadjusted RR and absolute incidence rates of HHF (per 1000 pts-year) in the major CV outcome trials with GLP-1Ra (blue) and SGLT-2i (red)Back to article page